No Data
No Data
Robert Taylor Nelsen resigned as non-executive director of Tengshengbo Medicine B (02137).
Tengshengbo Medicine-B (02137) released an announcement, Mr. Robert Taylor Nelsen...
Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference
Brii Biosciences (HKG:2137) presented new data from two phase 2 studies of BRII-179 for chronic hepatitis B virus infection at the European Association for the Study of the Liver Congress 2024, a June
Express News | Brii Bio Presents New Data From Its Ongoing Phase 2 Chronic Hepatitis B Trials at Easl™ Congress 2024
Tengshengbo Medicine-B (02137.HK) released new data from two phase 2 studies at the European Liver Research Association Congress in 2024.
On June 7th, National Business Daily announced that Tengshengbo Medicine-B (02137.HK) released new data from two Phase 2 studies at the European Liver Association Congress in 2024. These data evaluated the efficacy of BRII-179 and BRII-835 (elebsiran) combined therapy or BRII-179 as an adjuvant therapy combined with pegylated interferon α (PEG-IFNα) in the treatment of chronic hepatitis B virus (HBV) infection. Oral report data from a Phase 2 clinical trial showed that in some chronic HBV-infected subjects, the therapeutic vaccine, BRII
Tengsheng Pharmaceutical-B (02137.HK): BRII-835 and BRII-877 were recognized as breakthrough therapeutic varieties
On May 14, Gelonghui | Tengshengbo Pharmaceutical-B (02137.HK) announced that the Drug Evaluation Center of the China State Drug Administration will include the hepatitis B virus (“HBV”) specific broad-spectrum neutralizing monoclonal antibody BRII-877 (tobevibart) and the HBV-targeted small-interfering ribonucleic acid BRII-835 (elebsiran) under development as breakthrough therapeutic varieties. This is after the recombinant protein-based HBV immunotherapy BRII-179 was certified as a breakthrough treatment in November 2023, and the company is seeking functional treatment for HBV
Tengsheng Pharmaceutical-B (02137): The HBV-specific broad-spectrum neutralizing monoclonal antibody BRII-877 (tobevibart) and the HBV-targeted small interfering ribonucleic acid BRII-835 (elebsiran) were recognized as breakthrough therapeutic varieties
Tengsheng Pharmaceutical-B (02137) announced that the Drug Evaluation Center of China's State Drug Administration will be developing type B...
No Data